The PROPEL program aims to control gene expression through RNA structure, building logic-gated RNA therapies that switch on only where and when intended, without altering the genome. The post RNAV8 Bio Joins ARPA-H Team to Pioneer Programmable RNA Medicines appeared first on GEN - Genetic Engineering and Biotechnology News .
New enzymatic synthesis method developed at Wyss Institute expands RNA therapeutic capabilities while eliminating toxic byproducts of standard chemical synthesis
